匹伐他汀对冠心病合并非酒精性脂肪肝患者肝功能的影响

目的:观察匹伐他汀对肝功能正常冠心病(CHD)合并非酒精性脂肪肝(NAFLD)患者肝功能的影响。方法:选择我院CHD合并NAFLD且肝功能正常的患者205例为CHD+NAFLD组,根据NAFLD严重程度患者被分为轻度组87例、中度组64例、重度组54例,另选择同期在我院就诊的单纯CHD患者70例(CHD组)作为对照。四组均在常规治疗的基础上给予匹伐他汀治疗,治疗15d。观察四组治疗前后血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转移酶(γ-GT)水平和严重肝功能损害发生率。结果:治疗后CHD组、CHD+NAFLD轻、中、重度组血清ALT、AST、γ-GT水平均显著升高(P均=0.001),且四组治疗后ALT(45.89±11.36)U/L比(46.92±12.67)U/L比(46.35±11.95)U/L比(47.32±14.06)U/L]、AST(46.32±12.13)U/L比(48.54±13.49)U/L比(47.63±12.57)U/L比(48.66±13.54)U/L]、γ-GT(58.49±14.86)U/L比(57.62±11.38)U/L比(57.92±10.51)U/L比(58.52±13.8)U/L]水平及严重肝功能损害发生率(2.90%比3.57%比1.61%比3.92%)相比较差异均无统计学意义(P均>0.05)。结论:与单纯CHD患者比较,匹伐他汀用于肝功能正常CHD联合NAFLD患者未增加肝功能损害,具有良好的临床安全性。

Influence of pitavastatin on liver function in patients with coronary heart disease complicated non-alcoholic fatty liver disease

Objective:To observe influence of pitavastatin on liver function in patients with coronary heart disease(CHD)complicated non-alcoholic fatty liver disease(NAFLD)and normal liver function.Methods:A total of 205 CHD+NAFLD patients with normal liver function in our hospital were selected as CHD+NAFLD group.According to NAFLD severity,patients were divided into mild group(n=87),moderate group(n=64)and severe group(n=54),another 70 pure CHD patients in our hospital simultaneously were selected as CHD group for control.Above groups received pitavastatin based on routine treatment for 15d.Serum levels of alanine transaminase(ALT),aspartate transaminase(AST),γ-glutamyl transferase(γ-GT)before and after treatment,and incidence rate of severe liver dysfunction were observed among four groups.Results:Compared with before treatment,there were significant rise in serum levels of ALT,AST andγ-GT in CHD group,CHD+NAFLD mild group,moderate group and severe group after treatment,P=0.001 all.There were no significant difference in serum levels of ALT(45.89±11.36)U/L vs.(46.92±12.67)U/L vs.(46.35±11.95)U/L vs.(47.32±14.06)U/L],AST(46.32±12.13)U/L vs.(48.54±13.49)U/L vs.(47.63±12.57)U/L vs.(48.66±13.54)U/L],γ-GT(58.49±14.86)U/L vs.(57.62±11.38)U/L vs.(57.92±10.51)U/L vs.(58.52±13.8)U/L],and incidence rate of severe liver dysfunction(2.90%vs.3.57%vs.1.61%vs.3.92%)among CHD group,CHD+NAFLD mild group,moderate group and severe group,P>0.05 all.Conclusion:Compared with pure CHD patients,pitavastatin doesn’t increase liver function damage in CHD+NAFLD patients with normal liver function,which possesses good safety.